Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.

Journal Article (Journal Article)

Radiotherapy is a key component of cancer treatment. Because of its importance, there has been high interest in developing agents and strategies to further improve the therapeutic index of radiotherapy. DNA double-strand repair inhibitors (DSBRIs) are among the most promising agents to improve radiotherapy. However, their clinical translation has been limited by their potential toxicity to normal tissue. Recent advances in nanomedicine offer an opportunity to overcome this limitation. In this study, we aim to demonstrate the proof of principle by developing and evaluating nanoparticle (NP) formulations of KU55933, a DSBRI. We engineered a NP formulation of KU55933 using nanoprecipitation method with different lipid polymer nanoparticle formulation. NP KU55933 using PLGA formulation has the best loading efficacy as well as prolonged drug release profile. We demonstrated that NP KU55933 is a potent radiosensitizer in vitro using clonogenic assay and is more effective as a radiosensitizer than free KU55933 in vivo using mouse xenograft models of non-small cell lung cancer (NSCLC). Western blots and immunofluorescence showed NP KU55933 exhibited more prolonged inhibition of DNA repair pathway. In addition, NP KU55933 leads to lower skin toxicity than KU55933. Our study supports further investigations using NP to deliver DSBRIs to improve cancer radiotherapy treatment.

Full Text

Duke Authors

Cited Authors

  • Tian, X; Lara, H; Wagner, KT; Saripalli, S; Hyder, SN; Foote, M; Sethi, M; Wang, E; Caster, JM; Zhang, L; Wang, AZ

Published Date

  • December 21, 2015

Published In

Volume / Issue

  • 7 / 47

Start / End Page

  • 20211 - 20219

PubMed ID

  • 26575637

Pubmed Central ID

  • PMC4664156

Electronic International Standard Serial Number (EISSN)

  • 2040-3372

Digital Object Identifier (DOI)

  • 10.1039/c5nr05869d

Language

  • eng

Conference Location

  • England